In the study, researchers proposed using targeted micro RNA therapy to reduce the incidence of secondary cataracts by stopping them before they start developing.
The results of the study, published in Molecular Medicine, provide a “roadmap for potential therapies that control miRNA expression for the prevention of secondary cataracts,” according to the release.
The study was conducted in the University of Dayton’s Center for Tissue Regeneration and Engineering at Dayton, with Panagiotis Tsonis, PhD, biology professor and the center’s director as the principal investigator.
Related Articles on Cataracts:
NV’s New Eyes Now Offers LenSx Laser Cataract Surgery
Ophthalmologist on the Move: Dr. Kevin H. Merkley Joins TX’s UTMB Health Eye Center
Laser Cataract Surgery of New York Offers LenSx Surgery
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
